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Abstract
Objective: Our aim was to investigate the expression of apoptosis-associated proteins (bcl-2, bcl-xl, 
bax, bak, bid), apoptotic index (AI) and proliferation index (PI) in germinal center B-cell-like immu-
nophenotypic profile (GCB) and non-GCB of diffuse large B-cell lymphoma (DLBCL). 
Materials and Methods: The methylation status of the promoter region of O6-methylguanine-DNA 
yerine O6-methylguanine-DNA methyltransferase (MGMT) gene and its relation with immunopheno-
typic differentiation of DLBCLs were also investigated. 101 cases were classified as GCB (29 cases) or 
non-GCB (72 cases). Apoptosis-associated proteins and PI were determined by IHC, and TUNEL 
method was used to determine AI. MGMT methylation analysis was performed by real-time PCR.  
Results: The PI was significantly higher in GCB compared with non-GCB (p=0.011). Percentage of 
cells stained with bcl-6 was positively correlated with the percentage of cells expressing bcl-2 
(p=0.023), AI (p=0.006) and PI (p<0.001), while a significant negative correlation was observed 
with the percentage of cells expressing bax (p=0.027). The percentage of cells stained with MUM1 
showed a significantly positive correlation with the percentage of cells expressing bcl-xl (p=0.003), bid 
(p=0.002), AI (p<0.001), and PI (p=0.001). MGMT methylation analysis was performed in 95 
samples, and methylated profile was found in 31 cases (32.6%). GCB was found in 6 cases (22.2%) 
and non-GCB was determined in 25 cases (36.8%) out of 31 with MGMT methylated samples. There 
was no significant association between MGMT methylation status and immunophenotypic profiles 
(p=0.173). Introduction 
Diffuse large B-cell lymphoma (DLBCL) consti-
tutes the largest group of aggressive lymphomas in 
adults and 30-40% of adult non-Hodgkin lympho-
mas (NHL) in western countries [1,2]. DLBCLs 
show diversity in clinical presentation, morphology 
and genetic and molecular properties, which sug-
gests that these tumors represent a heterogeneous 
group of neoplasms rather than a single clinico-
pathologic entity [2,3]. Therefore, patients who are 
diagnosed as DLBCL could show remarkably differ-
ent history, clinical behavior and outcome [1]. 
Different mechanisms such as deregulation of 
cell cycle and apoptotic pathways are involved in 
the pathogenesis of DLBCL. As for the molecular 
pathogenesis of DLBCL, distinct chromosomal 
translocations and aberrant somatic hypermuta-
tions as well as numerical chromosomal anomalies 
such as duplications and deletions, which are also 
common to other malignancies, have been report-
ed [4-7]. 
DLBCL originates from germinal center (GC) and 
post-GC B-cells that normally have encountered 
with antigen [8,9]. Different methods are applied to 
determine B-cell differentiation antigens in DLBCL. 
In spite of the distinct advantages of cDNA and oligo-
nucleotide microarray techniques, immunohisto-
chemistry is a commonly used method to determine 
the GC B-cell-like (GCB) and non-GCB-like profiles 
because it is cheap and easily applied [10-12]. Hans 
et al. [11] reported that the classification of DLBCL 
into GCB and non-GCB profiles based on CD10/
bcl-6/MUM1 immunophenotypic differentiation is 
prognostically relevant to the cDNA classification in 
71% of GCB and in 88% of non-GCB. It is well known 
that the expression of bcl-6 and CD10 are associat-
ed with increased apoptosis and proliferation in 
lymphoid malignancies [13-18]. Bai et al. [10] 
reported that increased expression of apoptotic 
index (AI) in DLBCL with GCB profile is associated 
with high expression of the pro-apoptotic proteins 
(bax, bak, bid) and low expression of the antiapop-
totic protein (bcl-xl). However, data related to apop-
Conclusion: These results suggest that bcl-6 protein expression may be responsible for the high PI in 
GCB. Additionally, we found that apoptosis-associated proteins were not significantly associated with 
immunophenotypic profiles. (Turk J Hematol 2011; 28: 15-26)
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Özet
Amaç: Diffüz büyük B-hücreli lenfoma (DBBHL)’nın germinal merkez B-hücresi benzeri (GCB) ve 
non-GCB profillerinde apoptozis-ilişkili proteinlerin (bcl-2, bcl-xl, bax, bak, bid) ekspresyonunu, apop-
totic indeksi (AI) ve proliferasyon indeksi (PI)’ni araştırmaktır. Ayrıca, O6-methylguanine-DNA meth-
yltransferase (MGMT) geninin promoter bölgesinin metilasyon durumunu ve onun DBBHL’nın 
immünofenotipik diferansiyasyonuyla ilişkisini araştırmaktır. 
Yöntem ve Gereçler: 101 olgu GCB (29 olgu) ve non-GCB (72 olgu) olarak sınıflandırıldı. Apoptozis-
ilişkili proteinler ve PI immünohistokimyasal olarak saptandı ve TUNEL yöntemi AI’i belirlemek için 
kullanıldı. MGMT metilasyon analizi, real-time PCR ile gerçekleştirildi.  
Bulgular: PI, non-GCB ile karşılaştırıldığında GCB’de anlamlı şekilde yüksek saptandı (p=0.011). 
Bcl-6 ile p: PI, non-GCB ile karşılaştırıldığında GCB’de anlamlı şekilde yüksek saptandı (p=0.011). 
Bcl-6 ile pozitif boyanan hücrelerin yüzdesi bcl-2 (p=0.023), AI (p=0.006), ve PI (p<0.001) eksprese 
eden hücrelerin yüzdesi ile pozitif şekilde korele iken, bax eksprese eden hücrelerin yüzdesi ile nega-
tif korelasyon gözlendi (p=0.027). MUM1 ile boyanan hücrelerin yüzdesi bcl-xl (p=0.003), bid 
(p=0.002), AI (p<0.001) ve PI (p=0.001) eksprese eden hücrelerin yüzdesi ile anlamlı şekilde pozitif 
korelasyon gösterdi. MGMT metilasyon analizi 95 örneğe uygulandı ve metilasyon profili 31 olguda 
(%32.6) saptandı. 31 MGMT metile örnekten 6 olgunun (%22.2) GCB ve 25 olgunun (%36.8) non-
GCB olduğu belirlendi. MGMT metilasyon durumu ve immünofenotipik profiler arasında anlamlı ilişki 
saptanmadı (p=0.173).
Sonuç: Bu bulgular, bcl-6 protein ekspresyonunun GCB’de yüksek PI’inden sorumlu olabileceğini öne 
sürmektedir. Ek olarak, apoptozis-ilişkili proteinlerin immünofenotipik profilerle anlamlı ilişki 
göstermediğini saptadık. (Turk J Hematol 2011; 28: 15-26)
Anahtar kelimeler: Büyük B-hücreli lenfomalarda apoptosis ve proliferasyon
Geliş tarihi: 1 Mart 2010    Kabul tarihi: 29 Haziran 2010 
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immunophenotypic differentiation profiles is con-
siderably limited. Although the immunohistochemi-
cal expression of the apoptosis-associated bcl-2 
family proteins, bcl-2, bax, bak, and mcl1, was 
reported in DLBCLs [19-28], the expression levels of 
bcl-xl, bad, bid proteins and their relations with the 
status of apoptosis and proliferation were not exten-
sively analyzed in these lymphomas [25]. 
Altered DNA methylation profile has been com-
prehensively studied in the pathogenesis of cancer. 
Compared with normal cells, cancer cells frequent-
ly demonstrate genome-wide hypomethylation, 
hypermethylation of tumor suppressor gene, and 
loss of genomic imprinting [29]. In human cancers, 
the gene encoding the DNA-repair enzyme O6- 
methylguanine-DNA methyltransferase (MGMT) is 
not commonly mutated or deleted. Loss of MGMT 
expression is mainly due to epigenetic changes, 
specifically methylation of the promoter region 
[1,30]. MGMT protects cells from the toxicity of envi-
ronmental and therapeutic alkylating agents, which 
frequently target the O6 position of guanine. 
Inactivation of the MGMT gene via hypermethyl-
ation of its promoter region increases sensitivity of 
cells to the genotoxic effect of alkylating agents 
both in vitro and in vivo [1,3]. Recent research has 
focused on the relationship between MGMT-
methylation status and immunophenotypic differ-
entiation in DLBCLs [30,31].
The aim of this study was to investigate the 
expression profiles of apoptosis-associated proteins 
(bcl-2, bcl-xl, bax, bak, bid), apoptotic index (AI), 
and proliferation index (PI) in GCB and non-GCB 
immunophenotypic profiles of DLBCL. In addition, 
the methylation status of the promoter region of the 
MGMT gene and its relation with immunopheno-
typic differentiation of DLBCLs were investigated.
Materials and Methods
Materials
A total of 101 cases of de novo DLBCLs, diag-
nosed according to the World Health Organization 
(WHO) classification [2], were obtained from the 
files of the Department of Pathology, Faculty of 
Medicine, Ege University. Clinicopathological 
parameters for all patients were obtained from the 
pathology records. Ethical committee approval was 
obtained for this study.
Immunohistochemistry
For immunohistochemical staining, sections of 
5-μm-thickness were cut from formalin-fixed, paraf-
fin-embedded tissue blocks and placed on electro-
static-charged, poly-L-lysine-coated slides (X-traTM, 
Surgipath Medical Industries, Richmond, IL, USA). 
Sections were dehydrated at 60ºC for a minimum of 
2 hours (h). All immunostaining procedures includ-
ing deparaffinization and antigen retrieval process-
es were performed on BenchMark XT® automated 
stainer (Venatana Medical Systems, USA). After 
counterstaining of the slides with hematoxylin in 
automated stainer, dehydration, incubation in 
xylene and mounting processes were performed 
manually, and immunostaining procedure was 
completed. Bcl-6 (dilution: 1/20, clone: P1F6, Dako 
SA, Glostrup, Denmark), CD10 (dilution: 1/25, clone: 
56C6, Spring Bioscience, Pleasanton, CA, USA), 
IRF4/MUM1 (dilution: 1/25, clone: MUM1p, Dako SA, 
Glostrup, Denmark), bcl-2 (dilution: 1/40, clone: bcl-
2/100/DS, Novocastra, Newcastle upon Tyne, UK), 
bcl-xl (dilution: 1/20, clone: 2H12, Zymed, South San 
Francisco, CA, USA), bax (dilution: 1/200, code: 
A3533, Dako SA, Glostrup, Denmark), bak (dilution: 
1/100, code: A3538, Dako SA, Glostrup, Denmark), 
bid (dilution: 1/100, clone: NB110-40718, Novus, 
Littleton, CO, USA), and Ki-67 (dilution: 1/150, clone: 
MIB-1, Dako SA, Glostrup, Denmark) were used as 
primary antibodies.
Reactive lymph nodes and normal thymic tissue 
samples were used as positive controls. Negative 
controls were treated with the same immunohisto-
chemical method by omitting the primary antibody.
At least 10 fields selected on the basis that they 
contained immunopositive cells were counted by 
using the 40x objective lens on the light microscope. 
The number of immunopositive cells was divided 
by the total number of the counted cells, and the 
expression was defined as the percentage of posi-
tive cells. CD10, bcl-6, and MUM1 proteins were 
considered positive when at least 25% of neoplastic 
cells were immunopositive according to the previ-
ously defined criteria [12]. The CD10/bcl-6/MUM1 
immunophenotypes and their designation to GCB 
and non-GCB profiles were determined according 
to the classification by Hans et al. [11]. The expres-
sions of bcl-2, bcl-xl, bax, bak, and bid proteins 
were considered positive when at least 10% of neo-
plastic cells were immunopositive [10]. PI with 
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cells within the total number of the counted cells. 
Tunel Method
The terminal deoxynucleotidyl-transferase (TdT)-
mediated in situ labeling technique (TUNEL; in situ 
Cell Death Detection Kit, POD, Roche) was per-
formed on the 5-μm-thick sections of formalin-
fixed, paraffin-embedded tissue for demonstration 
of DNA fragmentation. Briefly, after deparaffiniza-
tion and dehydration, slides were rinsed in phos-
phate-buffered saline (PBS) (pH 7.4). The peroxi-
dase activity was blocked by incubation for 15 min-
utes (min) in 3% hydrogen peroxide in PBS at room 
temperature. Tissue sections were digested by incu-
bation for 30 min with proteinase K (20 μg/ml) at 
37ºC, and then were rinsed in PBS. TUNEL reaction 
mixture was prepared according to the manufac-
turer’s recommendations, and a mixture of 50 μL 
per slide was added. Slides were incubated for 1 h 
at 37ºC in dark. One positive control and two nega-
tive controls were included in each set of experi-
ments. Reactive lymph nodes were used as positive 
controls. Negative controls were treated similarly by 
omitting the TdT reaction step. Slides, once again, 
were rinsed in PBS. To examine the slides in light 
microscope, 50 μl Converter-peroxidase (POD) was 
added per slide and slides were incubated for 30 
min at 37ºC in humid and dark conditions. Slides 
were rinsed in PBS, and then were incubated with 
3,3’-diaminobenzidine tetrahydrochloride (DAB 
Substrate, Roche) for 10 min at room temperature. 
Slides were counterstained with Harris’ hematoxy-
lin and mounted. The evaluation of the results was 
performed as Bai et al. [32] had described previ-
ously. Morphologically intact TUNEL-positive cells 
were considered as positive and referred to as 
apoptotic cells. The number of apoptotic cells was 
recorded by using the 40X objective in at least 10 
randomly selected fields. The AI was expressed as 
a percentage of the number of apoptotic cells with-
in the total number of counted cells. 
O6-  Methylguanine-DNA Methyltransferase 
Methylation Analysis 
Genomic DNAs were extracted from four or five 
5-μm-thick sections of formalin-fixed, paraffin-
embedded tissue, using a commercial kit (QIAamp 
DNA Mini Kit, Qiagen, Valencia, CA). Briefly, after 
deparaffinization with xylene, tissue samples were 
digested with proteinase K treatment. DNAs that 
emerged from cells were collected in the column 
through ethanol treatment. Cellular remnants and 
chemical agents were removed by washing buffer, 
and genomic DNA was eluted in DNAase-free buffer 
and stored at -20ºC.
Commercial kit (EZ Methylation Gold-Kit, Zymo 
Research, Orange, CA) was used for bisulfite modifi-
cation of isolated DNA. Briefly, DNA concentration 
was measured and arranged to make 500 ng/μL, and 
130 μL conversion reagent was added to 20 μL DNA 
sample. Samples were incubated for 10 min at 98ºC 
and then for 2.5 h at 64ºC. Samples were transferred 
to column with 600 μL M-binding buffer. After homog-
enization, samples were centrifuged. Samples were 
rinsed with 100 μL M-wash buffer, and were then 
incubated in 200 μL M-desulfonation buffer for 20 
min at room temperature. After incubation, samples 
were rinsed two times, and then 10 μL M-elution buf-
fer was added. Sodium bisulfite-treated genomic 
DNA was stored at -20ºC.
Primer and probe sequences of the promoter 
region of MGMT gene were used, which target the 
localization of 1067 -1149 bp amplicon, as described 
by Esteller et al. (33) (GenBank Accession Number: 
X61657). Final reaction volume for analysis of both 
methylated and unmethylated profiles was per-
formed in 20 μL volume: 2 μl from each primer 
(final concentration: 0.5 μM), 2 μl TaqMan probe 
(final concentration: 0.2 μM), 4 μl LightCycler 
TaqMan Master mixture, 5 μl DNA sample, and 5 μl 
polymerase chain reaction (PCR)-grade water. The 
cycling conditions for methylation-specific PCR 
were: 10 min at 95ºC for Taq activation, followed by 
45 cycles of 95ºC for 10 seconds (sec), 60ºC for 20 
sec, and 72ºC for 1 sec for amplification. PCR prod-
ucts were run on a 3% agarose gel containing ethid-
ium bromide. 
Statistical Analysis
χ2 test, Mann-Whitney test and analysis of vari-
ance were applied for statistical analysis. Mann-
Whitney test was used to analyze the relationship of 
positivity of apoptosis-related proteins, PI (Ki-67) 
and AI with immunophenotypic differentiation pro-
files (CD10/bcl6/MUM1). Spearman correlation 
coefficient test was used to analyze any significant 
relationship between PI, AI and percentage of posi-
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6, and MUM1, whether evaluated as positive or 
negative using cut-off values. The results were con-
sidered as statistically significant when p<0.05. All 
the statistics were calculated using the SPSS 11.0 
program (SPSS 11.0 Inc., Chicago, IL, USA) for 
Windows. 
Results
Patients [53 males (52.5%), 48 females (47.5%)]
were aged between 19 and 84 (mean 55.53±14.12). 
Localization was nodal in 42 (41.6%) cases andex-
tranodal in 58 (57.4%) cases, while one case was 
unknown.
Immunohistochemical expression of bcl-6, CD10, 
MUM1, bcl-2, bcl-xl, bax, bak, and bid proteins was 
found in 51/101 (50.5%), 20/101 (19.8%), 49/101 
(48.5%), 32/101 (31.7%), 8/101 (7.9%), 67/101 
(66.3%), 82/101 (81.2%), and 67/99 (66.3%) cases, 
respectively (Figure 1 A-E). The mean PI was 46.15% 
(±32.82) as assessed by Ki-67 staining. The mean AI 
was 1.94% (±2.68) as determined by the TUNEL 
method (Figure 1 F).
Two major immunophenotypic profiles were dis-
tinguished according to the pattern of differentiation 
described by Hans et al. [11]: (a) GCB immunophe-
notypic profile: 29 cases (CD10+: 20 cases, CD10- /
bcl-6+ /MUM1-: 9 cases) and (b) non-GCB immuno-
phenotypic profile: 72 cases (CD10- /bcl-6-: 47 cases, 
CD10- /bcl-6+ /MUM1+: 25 cases) (Table 1).
Mann-Whitney test was used to analyze the asso-
ciation of two immunophenotypic differentiation 
profiles in relation to the AI, the expression levels of 
apoptosis-related proteins and PI (Ki-67) (Table 2). 
Compared to the non-GCB profile, the GCB profile 
was significantly associated with a higher PI 
(p=0.011). However, no other significant correla-
tions were determined between the two major dif-
ferentiation immunophenotypic profiles regarding 
AI and the expression levels of apoptosis-related 
proteins bcl-2, bcl-xl, bax, bak, and bid (p>0.3).
The percentage of cells stained by CD10, bcl-6 
and MUM1 were analyzed in relation to apoptosis-
related proteins, AI and PI by Spearman correlation 
coefficient test, regardless of previous evaluation 
with cut-off points to consider the results as positive 
or negative (Table 3). The expression of bcl6 was 
positively correlated with the expression of bcl2 
(r=0.226, p=0.023), the AI (r=0.272, p=0.006) and 
the PI (r=0.515, p<0.001), but a significantly nega-
tive correlation was observed with the expression 
of bax (r=-0.221, p=0.027). The expression of 
MUM1 showed significant positive correlation with 
the expression of bcl-xl (r=0.295, p=0.003), bid 
(r=0.313, p=0.002), AI (r=0.341, p<0.001), and PI 
Table 1. CD10/bcl-6/MUM1 immunophenotypic differentiation profiles 
(Total n=101)
Immunophenotypic differentiation profiles  n (%)
Germinal center B-cell-like profile
CD10+
 
bcl-6-
 MUM1-  1(1%)
   MUM1+  2  (2%)
 
bcl-6+
   MUM1-  13 (12.8%)
   MUM1+  4  (4%)
CD10-   bcl-6+ MUM1-  9  (8.9%)
TOTAL    29  (28.7%)
Non-germinal center B-cell-like profile
CD10-  bcl-6-
 MUM1+  18  (17.8%)
   MUM1-  29  (28.7%)
CD10-   bcl-6+ MUM1+  25  (24.8%)
TOTAL    72  (71.3%)
Table 2. The immunophenotypic differentiation profiles in relation to 
the apoptotic index (AI), the expression of apoptosis related proteins, 
and the proliferation index (PI) (Mann-Whitney test)
  Percentage of  Immunophenotypic   Mean  p
 positive    differentiation  rank  values
 expression  profile 
AI
 1.93  GCB  profile  51.33  0.941
 1.91  non-GCB  profile  50.87 
bcl-2
 18.52  GCB  profile  53.52  0.561
 15.69  non-GCB  profile  49.99 
bcl-xl
 1.86  GCB  profile  46.95  0.341
 6.16  non-GCB  profile  52.63 
bax
 43.07 GCB  profile  45.81  0.257
 50.87  non-GCB  profile  53.09 
bak
 58.34 GCB  profile  51.36  0.937
 60.80  non-GCB  profile  50.85 
bid
 42.00 GCB  profile  45.34  0.297
 51.81  non-GCB  profile  51.93 
PI (Ki-67)
 59.17  GCB  profile  62.66  0.011*
 41.69  non-GCB  profile  46.31 
GCB profile: Germinal center B-cell-like profile, Non-GCB profile: Non-germinal 
center B-cell-like profile
*indicates the statistically significant correlations (p<0.05)
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tion coefficient test was used to analyze the relations 
between apoptosis-related proteins, AI and PI. The 
expression of bcl-xl protein showed significant posi-
tive correlation with the expression of bak (r=0.198, 
p=0.047) and bid (r=0.198, p=0.049) proteins. The 
expression of bax protein showed significant positive 
correlation with the expression of bak (r=0.229, 
Figure 1. Immunohistochemical expression of antiapoptotic proteins (a) bcl2 and (b) bcl-xl and apoptotic proteins (c) bax, (d) bak and 
(e) bid in neoplastic cells of diffuse large B-cell lymphomas (a-d, x400; e, x200). (f) Staining of apoptotic cells by the TUNEL method (x400)
a
c
e
b
d
f
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expression of bak protein also showed significant 
positive correlation with the expression of bid 
(r=0.214, p=0.033) protein. The AI showed significant 
positive correlation with the PI (r=0.349, p<0.001). 
MGMT promoter methylation analysis was per-
formed in 95 patients with DLBCL (Figure 2). MGMT 
methylated profile was found in 31/95 (32.6%) sam-
ples while MGMT unmethylated profile was deter-
mined in 64/95 (67.4%) samples. The GCB profile 
was determined in 6 cases (22.2%) and non-GCB 
profile in 25 cases (36.8%) out of the 31 with MGMT 
methylated profile (Table 4). There was no signifi-
cant association between MGMT promoter methyla-
tion status and the two immunophenotypic differ-
entiation profiles (p=0.173) (Table 5). There was 
also no significant association between MGMT pro-
moter methylation status and the expression levels 
of apoptosis-related proteins, the AI and the PI 
(p>0.06).
Discussion
In the present study, we found that in DLBCLs, 
the GCB profile was significantly associated with a 
higher PI compared to the non-GCB profile. In addi-
tion, the percentage of cells reacting with the GC 
B-cell-related bcl-6 protein showed significant posi-
tive correlation with PI. The correlation between 
bcl-6 and proliferation is not conclusive in the pub-
lished data. A review of the literature indicates that 
bcl-6 could have a role both as stimulator or inhibi-
tor of cell cycle progression and proliferation [16,32-
37]. Some in vitro studies showed that bcl-6 expres-
sion was associated with delaying cell cycle pro-
gression and decreased proliferation [15,35]. Albagli 
et al. [16] demonstrated that bcl-6 mediates growth 
suppression associated with impaired S phase pro-
gression in human U2OS osteosarcoma cells. 
Hosokawa et al. [35] established Ba/F3 pro-B cells 
carrying a human bcl-6 transgene, and revealed that 
Table 3. Correlations between CD10, bcl-6 and MUM1 proteins and the apoptosis related proteins, the apoptotic index (AI), and the proliferation 
index (PI) (Spearman’s correlation test)
  bcl-2 bcl-xl bax  bak  bid AI PI
CD10
 r=0.092  r=0.050  r=0.055  r=-0.024  r=-0.001  r=0.130  r=0.148
  p=0.360 p=0.619  p=0.585 p=0.811 p=0.991  p=0.195  p=0.139
bcl-6
  r=0.226  r=0.176 r=-0.221  r=0.123  r=0.114 r=0.272 r=0.515
  p=0.023* p=0.078  p=0.027* p=0.220 p=0.260  p=0.006*  p<0.001*
MUM1
  r=0.122 r=0.295  r=0.009 r=0.152 r=0.313  r=0.341  r=0.330
  p=0.225  p=0.003*  p=0.932  p=0.129  p=0.002* p<0.001* p=0.001*
r, Spearman’s correlation coefficient. The positive or negative sign of the Spearman’s correlation coefficient r expresses significant (p<0.05) or nonsignificant (p=0.05 or 
p>0.05) positive or negative correlations between two continuous variables
*indicates the statistically significant correlations (p<0.05)
Figure 2. (a) Amplification curve after real-time PCR with methy-
leted specific primer and probe set. (b) Amplification curve after 
real-time PCR with unmethyleted specific primer and probe set
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of cyclin A2 and inhibits cell proliferation, though 
Shaffer  et al. [34] demonstrated that bcl-6 may 
induce cell cycle progression and maintain prolif-
eration by blocking the expression of the cyclin-
dependent kinase inhibitor p27 and by repressing 
blimp-1 expression, which decreases c-myc expres-
sion. Furthermore, Allman et al. [37] revealed that 
bcl-6 protein expression was 34-fold higher in rap-
idly proliferating GC B-cells than in the resting 
B-cells. Bai et al. [18] suggested that the resistance 
to antiproliferative signals through the P19 (ARF) 
-p53 pathway and downregulation of the expression 
of cyclin-dependent kinase inhibitor p27 are at least 
partly responsible for the association between bcl-6 
and increased proliferation in DLBCL. Xu et al. [38] 
investigated the role of bcl-6 gene rearrangement 
and bcl-6 expression in subgroups of DLBCLs and 
showed that DLBCLs with bcl-6 gene rearrange-
ment had higher proliferative activity than those 
without bcl-6 gene rearrangement. On the basis of 
the previously mentioned results, results of this 
study suggest that bcl-6 protein expression could be 
responsible for high PI in the GCB profile of DLBCL. 
Additionally, in this study, bcl-6 expression 
showed significant positive correlation with the AI 
and anti-apoptotic protein bcl-2 expression and 
negative correlation with pro-apoptotic protein bax 
expression. In association with the proliferation of 
bcl-6, the data in the literature indicates that bcl-6 
may have a role as stimulator or inhibitor of apopto-
sis [15,16,39-41]. Some studies showed that bcl-6 
may protect cells from apoptosis [39,41]. Kojima et 
al. [39] demonstrated that bcl-6 may have a stabiliz-
ing role to protect spermatocytes from heat shock- 
induced apoptosis in bcl-6-deficient mice. Baron et 
al. [41] showed that the human programmed cell 
death-2 (PDCD2) gene is a target of bcl-6 repression 
in Epstein-Barr virus-negative Burkitt lymphoma cell 
line expressing high levels of bcl-6. Furthermore, 
they immunohistochemically demonstrated the 
inverse relationship between bcl-6 and PDCD2 
expression in human tonsils [41]. Consequently, 
they proposed that bcl-6 may downregulate apopto-
sis by means of its repressive effects on PDCD2. 
However, some other studies suggested that high 
expression of bcl-6 may induce apoptosis [14-
16,40]. Albagli et al. [16] used the human osteosar-
coma cell line U2OS transfected with bcl-6 and 
demonstrated that bcl-6 mediates dose-dependent 
growth suppression, which is associated with 
impaired S phase progression and trigger of apopto-
sis. Yamochi et al. [14] showed that viability of CV-1 
and HeLa cells infected with a recombinant adeno-
virus expressing bcl-6 was markedly reduced due to 
apoptosis. Furthermore, induction of apoptosis by 
bcl-6 overexpression was preceded by downregula-
tion of apoptosis repressors bcl-2 and bcl-xl, which 
suggests that bcl-6 might also regulate the expres-
sion of these apoptosis repressors [14]. Bai et al. 
[18] found that high expression of bcl-6 shows sig-
nificant correlation with negative bcl-2 expression. 
They suggested that the association between 
increased bcl-6 expression and increased apoptosis 
in DLBCL might be due, at least to some extent, to 
the downregulation of bcl-2, which is induced by 
Table 4. The immunophenotypic differentiation profiles in relation to 
the MGMT methylation status
  MGMT methylation status  Total number of 
 Methylated  Unmethylated  cases
GCB  6 (22.2%)  21 (77.8%)  27
non-GCB  25 (36.8%)  43 (63.2%)  68
Total  31 (32.6%)  64 (67.4%)  95
MGMT, O6- methylguanine-DNA methyltransferase GCB profile: Germinal center 
B-cell-like profile, Non-GCB profile: Non-germinal center B-cell-like profile
Table 5. Association between MGMT methylation status and expres-
sion of CD10/bcl-6/MUM1 proteins (χ2 test)
Parameter   MGMT    p
   methylated  (%)  values*
CD10 expression  +  5 (26.3%)  0.514
 -  26  (34.2%) 
bcl-6 expression  +  14 (29.2%)  0.469
 -  17  (36.2%) 
MUM1 expression  +  12 (26.7%)  0.242
 -  19  (38.0%) 
CD10/bcl- CD10+/bcl-6-/MUM1-   0   0.729
6/MUM1   CD10+/bcl-6+/MUM1- 5  (38.5%)
coexpression CD10+/bcl-6-/MUM1+ 0 
 CD10+/bcl-6+/MUM1+ 0 
 CD10-/bcl-6-/MUM1+ 4  (23.5%) 
 CD10-bcl-6-/MUM1- 13  (46.4%) 
 CD10-/bcl-6+/MUM1- 1  (12.5%) 
 CD10-/bcl-6+/MUM1+ 8  (34.8%) 
MGMT, O6- methylguanine-DNA methyltransferase
*indicates the statistically significant correlations (p<0.05)
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studies, in this study, we determined that bcl-6 
expression shows a significantly positive correlation 
with bcl-2 expression. Moreover, we found that bcl-6 
expression shows significant negative correlation 
with pro-apoptotic protein bax expression. It is well 
known that apoptosis-related proteins bcl-2 and bcl-
xl show anti-apoptotic effect, whereas bax, bak and 
bid show pro-apoptotic function. These proteins, as 
members of the bcl-2 family, exert their specific 
effects by dimerizing with themselves or with each 
other [25]. If the balance favors the presence of free 
bcl-2, apoptosis is inhibited, whereas when bax pre-
dominates, apoptosis is initiated [25]. Thus, the ratio 
of the anti-apoptotic to the pro-apoptotic proteins 
determines whether a given cell will respond to or 
ignore an apoptotic stimulus [25]. On the basis of 
these results, we suggest that pro-apoptotic function 
of bcl-6 partly occurs independent of an anti-apoptot-
ic effect of bcl-2 and pro-apoptotic effect of bax. 
In this study, no significant correlations were 
determined between two major immunophenotypic 
differentiation profiles regarding AI and the expres-
sion levels of apoptosis-related proteins bcl-2, bcl-xl, 
bax, bak, and bid. However the percentage of cells 
positive for MUM1, which is major marker of non-
GCB immunophenotypic differentiation profile, 
showed a significantly positive correlation with the 
positivity percentage of anti-apoptotic protein bcl-xl, 
pro-apoptotic protein bid, AI, and PI. Bai et al. [10] 
determined that the expression of MUM1 showed 
significant negative correlation with the expression 
of  bax  and  bid and significant positive correlation 
with the expression of bcl-xl. They proposed that this 
result may provide an explanation for the significant 
positive correlation between MUM1 and bcl-xl expres-
sion in their study, because the MUM1 (IRF4) gene is 
also a nuclear factor-Kappa B target. Nuclear factor-
Kappa B, depending on the stimulus and the cellular 
context, can activate pro-apoptotic (e.g. CD95, 
CD95L, TRAIL receptors), anti-apoptotic (c-FLIP , bcl-
2, bcl-xl, c-IAP1, c-IAP2) and cell cycle (cyclin D1, 
cyclin D2, c-myc) genes [32]. This status may explain 
how MUM1 expression shows significant positive 
correlation with pro-apoptotic protein bid, AI, PI, as 
was also shown in the results of Bai et al. [10]. 
In this study, we determined that DLBCLs fre-
quently express bcl-2 family member apoptosis- 
related proteins as bcl-2 in 31.7%, bcl-xl in 7.9%, bax 
in 66.3%, bak in 81.2%, and bid in 66.3%. Bairey et al. 
[25] examined the role of bcl-2 family proteins in 
aggressive NHLs and determined that of the entire 
group of 44 samples, 25 (57%) showed bcl-2 stain-
ing, 11 (25%) showed bcl-xl staining, 17 (39%) 
showed  bax staining, and 16 (36%) showed bak 
staining. Among these proteins, bcl-2, the most 
exclusively investigated, is a potent suppressor of 
apoptosis and is determined in unexpectedly high 
levels probably in all cancers of humans [50]. 
Simonian et al. [43] suggested that bcl-2 and bcl-xl 
can downregulate or upregulate apoptosis. Sclaifer 
et al. [44] showed that all cases with a positive 
expression of bax expressed either bcl-2 or mcl-1 
anti-apoptotic proteins, suggesting that the pres-
ence of bax in the tumor cells must be associated 
with apoptosis-inhibiting proteins, allowing malig-
nant cell survival. Kiberu et al. [22] investigated the 
correlation between apoptosis, proliferation and 
bcl-2 expression in NHLs, and they suggested that 
expression of bcl-2 is not necessarily related to low 
levels of apoptosis, as some bcl-2 positive high-
grade tumors also had high levels of apoptosis. 
Nevertheless, they found that the majority of lym-
phomas expressing bcl-2 had average levels of 
apoptosis [22]. These results suggested that bcl-2 
independent apoptosis is an important factor influ-
encing cell death in many NHLs [22]. Overall results 
of previous studies [10,19,22-27] and our results 
indicate that the expressions of bcl-2 family proteins 
are variable and heterogeneous in DLBCL. The dual 
effect of bcl-2 family proteins may show individual 
variation in the pathogenesis and prognosis of 
DLBCLs.
In this study, we found that the AI showed sig-
nificant positive correlation with the PI. This result is 
correlated with previously reported results 
[10,22,45]. However, we were unable to show any 
relation between apoptosis-related proteins and PI. 
In this study, we determined that MGMT pro-
moter methylation was detected in 32.6% of cases. 
MGMT methylation was reported at a frequency 
from 36% to 52% in Western populations in previous 
studies [1,3,30,46,47]. Higher rates (75.9%) were 
found in Middle Eastern populations [38]. This sta-
tus may be explained by the differences in etiologic 
factors such as viral infections and exposure to envi-
ronmental factors as well as differences in the 
genetic susceptibility. Furthermore, substantial eth-
nic differences existed with respect to molecular 
features of malignant tumors [31,48-50].
Türk et al.
Apoptosis, proliferation in large B-cell lymphoma Turk J Hematol 2011; 28: 15-26 23No significant association between MGMT pro-
moter methylation status and the two immuno-
phenotypic differentiation profiles was observed in 
this study. Al-Kuraya et al. [31] investigated the 
interrelationship between MGMT methylation sta-
tus and immunohistochemical coexpression of 
CD10/bcl-6, and they did not show a significant 
association. Furthermore, Al-Kuraya et al. deter-
mined that their frequency of GCB profile DLBCL 
(13%) was somewhat lower than described in pre-
vious studies. They also found a much higher rate 
of MGMT methylation in their patients (75.9%) as 
compared with previous studies [1,3,30,31,46,47]. 
In our study, no significant association was found 
between MGMT promoter methylation status and 
the expression levels of apoptosis-related proteins, 
the AI and the PI. There is no similar previous study 
searching the relation of MGMT promoter methyla-
tion and expression levels of apoptosis-related 
proteins, the AI and the PI. Further studies could 
be done to elucidate the role of MGMT promote 
methylation in DLBCLs.
In summary, these results suggest that bcl-6 pro-
tein expression may be responsible for the high PI 
in the GCB profile of DLBCLs. Additionally, we 
found that expression status of apoptosis-related 
bcl-2 family proteins (bcl-2, bcl-xl, bax, bak, bid) 
was not significantly associated with the immuno-
phenotypic differentiation profiles. We also deter-
mined that there was no significant association 
between MGMT promoter methylation status and 
the immunophenotypic differentiation profiles of 
DLBCLs. 
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